Clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B cell lymphoma.
10.7534/j.issn.1009-2137.2014.06.022
- Author:
Peng YUAN
1
;
Zheng-Ping YU
2
;
Tian-Hua YUE
1
;
Yan-Hua XIAO
1
;
Bao-An CHEN
3
,
4
Author Information
1. Department of Interventional Radiology, Jianhu County People's Hospital, Jianhu 224700, Jiangsu Province, China.
2. Department of Hematology, Zhongda Hospital Affiliated to Southeast University Nanjing, Nanjing 210000, Jiangsu Province, China.
3. Department of Hematology, Zhongda Hospital Affiliated to Southeast University Nanjing, Nanjing 210000, Jiangsu Province, China. E-mail: cba8888@hotmail.com
4. bachen@seu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Central Nervous System Neoplasms;
drug therapy;
Humans;
Idarubicin;
administration & dosage;
Lymphoma, Large B-Cell, Diffuse;
drug therapy;
Methotrexate;
administration & dosage;
Remission Induction;
Treatment Outcome
- From:
Journal of Experimental Hematology
2014;22(6):1621-1623
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to investigate the clinical efficacy of idarubicin combined with methotrexate for treatment of patients with central nervous system diffuse large B-cell lymphoma. A total of 88 patients with central nervous system diffuse large B-cell lymphoma was selected, out of them 54 patients received idarubicin combined with methotrexate and were selected as A group, other 34 patients received only methotrexate and were selected as B group (control group). Clinical efficacy and safety were compared after treatment. The results showed that in A group 84 patients achieved complete remission (CR), 5 patients archived partial remission (PR), the total remission rate of A group was 72.2%; in B group 10 patients achieved complete remission (CR), 4 patients archived partial remission (PR), the total remission rate of B group was 41.2%; the average survival time of A group was 33.172 months, and the average survival time of B group was 26.305 months, the former was significantly higher than latter (P < 0.05). It is concluded that idarubicin combined with methotrexate for the patients with central nervous system diffuse large B-cell lymphoma is effective and safe, and may be used in clinic.
